Eli Lilly's Zepbound Demonstrates Potential as Sleep Apnea Treatment

Eli Lilly's Zepbound Shows Promise for Sleep Apnea

The pharmaceutical giant Eli Lilly has reported positive outcomes in late-stage trials of its weight loss drug Zepbound, hinting at its potential as a treatment for sleep apnea.

Major Milestone Towards FDA Approval

The company plans to present the trial data at an upcoming medical conference and submit it to the U.S. Food and Drug Administration by mid-year, a crucial move in the path to regulatory approval.